Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

Going deeper into the new world of genetic , the FDA has for the second time approved a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. And more could be on the way.

The drug is larotrectinib (Vitrakvi), from Loxo Oncology (NASDAQ: LOXO), and it has been designed to knock out tumors in which a gene called NTRK has abnormally fused to another gene. The abnormality occurs in up to 1 percent of all solid tumor types, including cancers of the kidney, bladder, stomach, and lung.

The FDA has approved… Read more »


Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.